C11 Sodium Acetate PET/CT Imaging of PCa

This is an expanded access study under an IND with a total of 300 participants with prostate
cancer. Eligible participants will undergo baseline assessments at enrollment. Study
participants will receive 11C-Sodium Acetate and will undergo a PET/CT imaging study. All
patients referred by Oncologists and Urologists will be screened by a UCLA Nuclear Medicine
physician and then accepted for scanning if clinically appropriate. The following steps will
take place.

1. Informed consent will be obtained.

2. Vital signs (heart rate, blood pressure, respiratory rate, pulse oxymetry) will be
recorded.

3. Participant will be injected with 20 - 40mCi of 11C-Sodium Acetate intravenously (i.v.).

4. PET/CT Scans will be performed with or without oral and IV contrast. All investigational
scans will be read by at least one board-certified nuclear medicine physician with
established expertise in PET/CT of at least 5 years' experience. Fifteen minutes after
injection of 11C-Sodium Acetate, the investigators will acquire a scan. Emission images
will be acquired for 3-5min/bed position. Intravenous and oral contrast will be given
for the CT portion of the study.

5. Vital signs (heart rate, blood pressure, respiratory rate, pulse oxymetry) will be
recorded following the completion of the scan.

6. Within 24-48 hours of PET/CT imaging, a follow-up telephone call or email will be
conducted to discuss any side effects or reactions to the investigational agent.

Inclusion Criteria:

- Diagnosed prostate cancer

- Able to remain still for duration of each imaging procedure (about 30 minutes)

Exclusion Criteria:

- Inability to complete the needed investigational and standard-of-care imaging
examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)

- Any additional medical condition, serious concurrent illness, or other extenuating
circumstance that, in the opinion of the Investigator, may significantly interfere
with study compliance.